DalsnaFinance

SciBase Submits FDA 510(k) to Expand Nevisense into the Largest Skin Cancer Market

Markets PR Newswire By PR Newswire 01 Jul 2026 06:53 1 min read
SciBase Submits FDA 510(k) to Expand Nevisense into the Largest Skin Cancer Market

STOCKHOLM, July 1, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB) a leader in AI-based devices for detection and prevention in dermatology, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand...

STOCKHOLM, July 1, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB) a leader in AI-based devices for detection and prevention in dermatology, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.